Classification and pharmacology of antiarrhythmic drugs

American Heart Journal

Volumn 140, Issue 1, 2000, Pages 12-20

  Kowey, Peter R ^a   Marinchak, Roger A ^a   Rials, Seth J ^a   Bharucha, David B ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALINIDINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATROPINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; LIDOCAINE; MEXILETINE; MORACIZINE; NADOLOL; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TOCAINIDE; VERAPAMIL;

ARTICLE; BRADYCARDIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0033914110     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.106640     Document Type: Article

References (33)

1. Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jensen E, Olesen KH, editors. Symposium on cardiac arrhythmias. Sweden: Astra; 1970. p. 449-72.
2. Hondeghem LM. Antiarrhythmic agents: modulated receptor applications. Circulation 1987;75:514-20.
3. Singh BN. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents. Am J Cardiol 1993;72:8A-18A.
4. Jaillon P, Winkle RA. Electrophysiologic comparative study of pro-cainamide and N-acetyl procainamide in anesthetized dogs: concentration-response relationships. Circulation 1975;60:1385-94.
5. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51.
6. Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation 1991;83:1499-509.
7. Hoffman BF, Bigger JT Jr. Digitalis and allied cardiac glycosides. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacologic basis of therapeutics. New York: Pergamon Press; 1990. p. 862-79.
8. Siddoway LA. Pharmacologic principles of antiarrhythmic drugs. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmias: mechanisms, diagnosis and management. Baltimore: Williams & Wilkins; 1995. p. 355-68.
9. Reiffel JA, Coromilas J, Zimmerman JM. Drug-device interaction: clinical considerations. PACE 1985;8:369-73.
10. Spivak C, Gottlieb S, Miura DS, et al. Flecainide toxicity. Am J Cardiol 1984;53:329-30.
11. Lindenbaum J, Mellow MH, Blackstone MO, et al. Variability in biological availability of digoxin from four preparations. N Engl J Med 1971;285:1344-7.
12. Grubb BP. Recurrence of ventricular tachycardia after conversion from proprietary to generic procainamide. Am J Cardiol 1989;63:1532-3.
13. Woosley RL. Antiarrhythmic agents: pharmacokinetics and pharma-codynamics. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: WB Sounders; 1990. p. 872-82.
14. Meffin PJ, Robert EW, Winkle RA, et al. Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm 1979;7:29-46.
15. Kessler KM, Kissane B, Cassidy J, et al. Dynamic variability of binding of antiarrhythmic drugs during acute myocardial infarction. Circulation 1984;70:472-8.
16. Marcus FI. Drug interactions with amiodarone. Am Heart J. 1983;106:924-9.
17. Benet LZ, Williams RL Design and optimization of dosage regimens: pharmacokinetic data. In: Gilman AG, Rail TW, Nies AS, et al, editors. The pharmacologic basis of therapeutics. New York: Pergamon Press; 1990. 1650-735.
18. Connolly SJ, Kates RE, Lebsack CS, et al. Clinical pharmacology of propafenone. Circulation 1983;68:589-96.
19. Lennard MS, Silas JH, Freestone S, et al. Oxidative phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med 1982;307:1558-60.
20. Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990;322:4-1768.
21. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 1975;17:722-30.
22. Price Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
23. Funck-Brentano C, Kroemer HK, Pavlou H, et al. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 1989;27:435-44.
24. Naccarelli GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996;78(suppl):12-6.
25. Naccarelli GV, Dougherty AH. Amiodarone: a review of its pharmacologic, antiarrhythmic, and adverse effects. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmia: mechanisms, diagnosis, and management. Baltimore: Williams & Wilkins; 1995. p. 434-49.
26. Riddell JG, McAllister CB, Wilkinson GR, et al. Constant plasma drug concentrations: a new technique with application to lidocaine. Ann Intern Med 1984;100:25-8.
27. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
28. Doering W. Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med 1979;301:400-4.
29. Lowenthal DT, Kim KE, Affrine MB, et al. Overview of physiology in senescence. Chest 1983;83:408-9.
30. Vestal RE, Wood AJ, Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 1979;26:181-6.
31. Abemethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 1981;102:740-4.
32. Waxman HL, Beauregard LM, DaTorre SD, et al. Congestive heart failure, cardiomyopathy, and ventricular arrhythmia. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmia: mechanisms, diagnosis and management. Baltimore: Williams & Wilkins; 1995. p. 1188-205.
33. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973;78:499-508.